PTCT

PTC Therapeutics, Inc. NASDAQ Listed Jun 20, 2013

Healthcare ·Biotechnology ·US · ptcbio.com

$66.61

After hrs $66.57 -0.06%

Mkt Cap $5.5B

52w Low $37.94 57.8% of range 52w High $87.50

50d MA $67.70 200d MA $66.68

P/E (TTM) 7.6x

EV/EBITDA 6.3x

P/B —

Debt/Equity -2.4x

ROE -332.5%

P/FCF 8.6x

RSI (14) —

ATR (14) —

Beta 0.55

50d MA $67.70

200d MA $66.68

Avg Volume 1.3M

About

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeut…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 19, 2026	AMC	-0.21	-1.67	-695.2%	69.90	-2.1%	+1.1%	+0.9%	-1.3%	-3.1%	-2.6%	—
Nov 4, 2025	AMC	-1.19	0.20	+116.8%	67.72	+3.4%	+6.0%	+7.2%	+6.0%	+7.0%	+9.0%	—
Aug 7, 2025	AMC	-1.07	-0.83	+22.4%	50.36	-10.6%	-9.9%	-14.0%	-10.1%	-4.3%	-3.3%	—
May 6, 2025	AMC	-1.08	10.04	+1029.6%	36.19	+8.9%	+12.6%	+17.5%	+22.2%	+27.1%	+28.2%	—
Feb 27, 2025	AMC	-1.12	-0.24	+78.6%	50.57	-10.1%	+9.3%	+4.5%	+2.4%	+2.7%	+4.4%	—
Nov 7, 2024	AMC	-1.54	-1.39	+9.7%	42.96	+6.2%	+3.1%	+4.4%	+3.9%	+2.5%	-1.4%	—
Aug 8, 2024	AMC	-1.00	-1.16	-16.0%	32.45	-9.5%	-3.6%	-3.5%	-1.8%	-2.1%	+1.8%	—
Apr 25, 2024	AMC	-1.21	-1.20	+0.8%	25.49	+5.9%	+12.1%	+26.1%	+26.1%	+34.0%	+31.9%	—
Feb 29, 2024	AMC	0.29	-0.24	-182.8%	28.19	-6.0%	+13.3%	+9.9%	+11.0%	+9.5%	+9.1%	—
Oct 26, 2023	AMC	-0.85	-1.76	-107.1%	23.95	-19.2%	-22.7%	-21.8%	-21.7%	-23.0%	-24.6%	—
Aug 3, 2023	AMC	-1.58	-2.66	-68.4%	40.32	+1.9%	-4.0%	-5.8%	-3.2%	-1.2%	+0.8%	—
Apr 27, 2023	AMC	-1.64	-1.88	-14.6%	52.64	+5.2%	+4.7%	+4.8%	+4.4%	+5.3%	+6.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 30	Jefferies	Downgrade	Buy → Hold	—	$66.13	$65.34	-1.2%	-0.7%	+3.0%	+4.0%	+2.5%	+4.2%
Feb 23	Morgan Stanley	Maintains	Overweight → Overweight	—	$70.66	$69.98	-1.0%	-0.2%	-2.4%	-4.1%	-3.6%	-3.5%
Feb 20	Wells Fargo	Maintains	Overweight → Overweight	—	$69.90	$68.45	-2.1%	+1.1%	+0.9%	-1.3%	-3.1%	-2.6%
Feb 20	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$69.90	$68.45	-2.1%	+1.1%	+0.9%	-1.3%	-3.1%	-2.6%
Feb 20	BofA Securities	Maintains	Buy → Buy	—	$69.90	$68.45	-2.1%	+1.1%	+0.9%	-1.3%	-3.1%	-2.6%
Jan 28	Barclays	Upgrade	Equal Weight → Overweight	—	$75.49	$76.87	+1.8%	+0.1%	+1.2%	+0.1%	-0.8%	-0.9%
Dec 1	RBC Capital	Downgrade	Outperform → Sector Perform	—	$85.99	$83.19	-3.3%	-7.9%	-8.7%	-11.9%	-9.5%	-10.2%
Nov 6	Barclays	Maintains	Equal Weight → Equal Weight	—	$71.77	$71.79	+0.0%	+1.1%	+0.0%	+1.0%	+2.9%	+4.4%
Nov 5	Wells Fargo	Maintains	Overweight → Overweight	—	$67.72	$70.00	+3.4%	+6.0%	+7.2%	+6.0%	+7.0%	+9.0%
Nov 5	Citigroup	Maintains	Neutral → Neutral	—	$67.72	$70.00	+3.4%	+6.0%	+7.2%	+6.0%	+7.0%	+9.0%
Nov 5	TD Cowen	Maintains	Hold → Hold	—	$67.72	$70.00	+3.4%	+6.0%	+7.2%	+6.0%	+7.0%	+9.0%
Nov 5	RBC Capital	Maintains	Outperform → Outperform	—	$67.72	$70.00	+3.4%	+6.0%	+7.2%	+6.0%	+7.0%	+9.0%
Nov 5	Goldman Sachs	Maintains	Sell → Sell	—	$67.72	$70.00	+3.4%	+6.0%	+7.2%	+6.0%	+7.0%	+9.0%
Oct 28	Jefferies	Maintains	Buy → Buy	—	$67.08	$66.86	-0.3%	+0.6%	+0.4%	+1.5%	+1.8%	+1.3%
Sep 3	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$52.43	$52.88	+0.9%	+6.0%	+10.6%	+9.2%	+8.6%	+11.4%
Aug 20	BofA Securities	Maintains	Buy → Buy	—	$49.59	$49.38	-0.4%	-1.5%	-1.4%	+2.0%	-0.6%	-0.3%
Aug 20	Morgan Stanley	Maintains	Overweight → Overweight	—	$49.59	$49.38	-0.4%	-1.5%	-1.4%	+2.0%	-0.6%	-0.3%
Aug 20	Wells Fargo	Maintains	Overweight → Overweight	—	$49.59	$49.38	-0.4%	-1.5%	-1.4%	+2.0%	-0.6%	-0.3%
Aug 8	RBC Capital	Maintains	Outperform → Outperform	—	$50.36	$45.00	-10.6%	-9.9%	-14.0%	-10.1%	-4.3%	-3.3%
Aug 8	Wells Fargo	Maintains	Overweight → Overweight	—	$50.36	$45.00	-10.6%	-9.9%	-14.0%	-10.1%	-4.3%	-3.3%
Aug 8	Morgan Stanley	Maintains	Overweight → Overweight	—	$50.36	$45.00	-10.6%	-9.9%	-14.0%	-10.1%	-4.3%	-3.3%
Jul 29	BofA Securities	Maintains	Buy → Buy	—	$44.34	$47.50	+7.1%	+11.2%	+14.9%	+17.5%	+17.6%	+17.8%
Jul 29	Truist	Maintains	Buy → Buy	—	$44.34	$47.50	+7.1%	+11.2%	+14.9%	+17.5%	+17.6%	+17.8%
Jul 29	Barclays	Maintains	Equal Weight → Equal Weight	—	$44.34	$47.50	+7.1%	+11.2%	+14.9%	+17.5%	+17.6%	+17.8%
Jul 29	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$44.34	$47.50	+7.1%	+11.2%	+14.9%	+17.5%	+17.6%	+17.8%
Jul 29	Wells Fargo	Maintains	Overweight → Overweight	—	$44.34	$47.50	+7.1%	+11.2%	+14.9%	+17.5%	+17.6%	+17.8%
Jul 29	UBS	Maintains	Buy → Buy	—	$44.34	$47.50	+7.1%	+11.2%	+14.9%	+17.5%	+17.6%	+17.8%
Jul 28	Citigroup	Maintains	Neutral → Neutral	—	$44.74	$44.82	+0.2%	-0.9%	+10.2%	+13.9%	+16.5%	+16.5%
May 27	Wells Fargo	Maintains	Overweight → Overweight	—	$45.93	$47.43	+3.3%	+4.2%	+2.9%	+6.4%	+5.6%	+6.3%
May 9	BofA Securities	Upgrade	Neutral → Buy	—	$42.51	$44.29	+4.2%	+4.0%	+8.2%	+9.1%	+10.0%	+6.6%
May 8	Barclays	Maintains	Equal Weight → Equal Weight	—	$40.76	$40.72	-0.1%	+4.3%	+8.5%	+12.9%	+13.8%	+14.7%
May 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$36.19	$39.40	+8.9%	+12.6%	+17.5%	+22.2%	+27.1%	+28.2%
May 7	Baird	Maintains	Outperform → Outperform	—	$36.19	$39.40	+8.9%	+12.6%	+17.5%	+22.2%	+27.1%	+28.2%
May 7	RBC Capital	Maintains	Outperform → Outperform	—	$36.19	$39.40	+8.9%	+12.6%	+17.5%	+22.2%	+27.1%	+28.2%
May 7	Citigroup	Upgrade	Sell → Neutral	—	$36.19	$39.40	+8.9%	+12.6%	+17.5%	+22.2%	+27.1%	+28.2%
May 7	JP Morgan	Maintains	Overweight → Overweight	—	$36.19	$39.40	+8.9%	+12.6%	+17.5%	+22.2%	+27.1%	+28.2%
Apr 22	RBC Capital	Maintains	Outperform → Outperform	—	$48.19	$48.00	-0.4%	+0.0%	+3.7%	+2.8%	+2.8%	+3.3%
Mar 31	JP Morgan	Maintains	Overweight → Overweight	—	$54.24	$52.89	-2.5%	-6.0%	-14.1%	-10.8%	-13.8%	-20.3%
Mar 14	JP Morgan	Maintains	Overweight → Overweight	—	$52.76	$53.50	+1.4%	+3.3%	+8.4%	+5.1%	+8.0%	+7.3%
Mar 11	BofA Securities	Upgrade	Underperform → Neutral	—	$52.49	$53.12	+1.2%	+0.2%	+2.1%	+0.5%	+3.8%	+8.9%
Feb 28	JP Morgan	Maintains	Overweight → Overweight	—	$50.57	$45.45	-10.1%	+9.3%	+4.5%	+2.4%	+2.7%	+4.4%
Feb 18	RBC Capital	Maintains	Outperform → Outperform	—	$51.82	$52.50	+1.3%	-4.6%	-2.7%	-2.8%	-2.2%	-3.5%
Feb 12	Citigroup	Maintains	Sell → Sell	—	$48.64	$47.64	-2.1%	+0.6%	+2.1%	+6.5%	+1.6%	+3.7%
Feb 3	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$45.88	$45.86	-0.0%	+9.0%	+7.6%	+9.0%	+8.5%	+7.8%
Jan 15	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$41.81	$42.92	+2.7%	+1.1%	+3.0%	+4.9%	+8.2%	+7.8%
Dec 13	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$47.36	$49.34	+4.2%	-2.1%	+2.6%	-0.7%	-4.0%	-4.5%
Dec 4	Goldman Sachs	Maintains	Sell → Sell	—	$50.29	$49.89	-0.8%	-0.9%	-3.8%	-4.5%	-4.4%	-0.6%
Dec 4	Citigroup	Maintains	Sell → Sell	—	$50.29	$49.89	-0.8%	-0.9%	-3.8%	-4.5%	-4.4%	-0.6%
Dec 3	Barclays	Maintains	Equal Weight → Equal Weight	—	$52.07	$53.33	+2.4%	-3.4%	-4.2%	-7.0%	-7.7%	-7.7%
Dec 3	UBS	Maintains	Buy → Buy	—	$52.07	$53.33	+2.4%	-3.4%	-4.2%	-7.0%	-7.7%	-7.7%

Recent Filings

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Morgan Stanley appointed a new executive (details in exhibit), which could signal strategic leadership changes affecting future direction and investor confidence in management's vision.

Mar 25

8-K

PTC Therapeutics, Inc. -- 8-K Filing

PTC Therapeutics reported strong Q4 2025 results and continued momentum from its Sephience product launch, signaling successful commercial execution and positive revenue growth trajectory for investors.

Feb 19

8-K · 7.01 ! Medium

PTC Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure

PTC Therapeutics withdrew its Translarna resubmission for nonsense mutation DMD after FDA feedback, eliminating a potential revenue driver and signaling development challenges for this therapy.

Feb 12

Data updated apr 26, 2026 9:07pm · Source: massive.com